Clinical trials assessing the combination of selinexor with immunotherapy
Cancers | Indication | Immunotherapy combination with selinexor | NCT number | Status* | Phase |
---|---|---|---|---|---|
Haematological cancers | Double hit & triple hit lymphoma | Rituximab + CHOP | NCT05974085 | Recruiting | II |
RR B cell lymphoma | Rituximab + GDP or rituximab + DHAOx | NCT02741388 | Completed | I | |
RR B cell lymphoma | Rituximab + ICE | NCT02471911 | Completed | I | |
EBV+ DLBCL | Rituximab + CHOP | NCT05577364 | Recruiting | I/II | |
RR DLBCL & indolent NHL | Rituximab + lenalidomide | NCT05265975 | Recruiting | I/II | |
RR B-NHL | CD19-CAR-T | NCT05322330 | Unknown | II | |
RRDLBCL | Rituximab + GDP | NCT04442022 | Recruiting | II/III | |
GCB-DLBCL | Rituximab + CHOP | NCT05422066 | Recruiting | II | |
R/RCLL NHL | Ibrutinib | NCT02303392 | Unknown | I | |
RR multiple myeloma (MM) | Daratumumab, pomalidomide or carfilzomib + dexamethasone | NCT04661137 | Recruiting | II | |
Newly diagnosed (ND) MM | Lenalidomide + bortezomib + dexamethasone | NCT05422027 | Recruiting | I/II | |
RR MM | Lenalidomide, thalidomide, or pomalidomide + dexamethasone | NCT04941937 | Recruiting | II | |
RR MM | Pomalidomide + dexamethasone | NCT05028348 | Recruiting | III | |
RR MM | Mezigdomide + dexamethasone | NCT02343042 | Recruiting | I/II | |
RR MM | Daratumumab + bortezomib + dexamethasone | NCT03589222 | Unknown | II | |
Daratumumab + carfilzomib + dexamethosone | NCT04756401 | Active, not recruiting | II | ||
Lenalidomide | NCT04519476 | Recruiting | I | ||
RR MM | Daratumumab, pomalidomide or carfilzomib + dexamethasone | NCT04925193 | Active, not recruiting | II | |
ND MM | Lenalidomide or bortezomib + dexamethasone | NCT04717700 | Active, not recruiting | II | |
High risk, ND MM | Daratumumab + bortezomib + dexamethasone | NCT06169215 | Recruiting | II | |
ND MM with extramedullary disease | Lenalidomide + bortezomib + dexamethasone | NCT05900882 | Recruiting | II | |
RR extramedullary MM | BCMA-CAR-T | NCT05201118 | Unknown | I | |
MM & myeloma-associated amyloidosis | Lenalidomide + dexamethasone | NCT05820763 | Withdrawn | II | |
ND MM | Daratumumab + lenalidomide + dexamethasone | NCT04782687 | Active, not recruiting | II | |
Solid cancers | Advanced solid malignancy (not including brain tumors) | IpilimumabNivolumabPembrolizumabAdditional chemotherapy arms | NCT02419495 | Terminated | I |
NSCLC or CRC | PembrolizumabFOLFIRIDocetaxel | NCT04256707 | Recruiting | I/II | |
ND HCC | Bevacizumab + atezolizumab | NCT05093608 | Terminated | I | |
Advanced/Metastatic solid malignancy | Nivolumab + ipilimumab | NCT04850755 | Unknown | I | |
Advanced/Metastatic urothelial carcinoma | Pembrolizumab | NCT04856189 | Recruiting | I/II | |
Alveolar soft part sarcoma | Atezolizumab | NCT05333458 | Recruiting | II | |
Recurrent advanced melanoma | Pembrolizumab | NCT04768881 | Terminated | II |
CAR: chimeric antigen receptor; DLBCL: diffuse large B cell lymphoma; RR: relapsed and refractory; BCMA: B cell maturation antigen; GCB: germinal center B-cell; NHL: non-Hodgkin lymphoma. *Trial status provided is according to information on clinicaltrials.gov as of (Date—01/23/2025); respective trial sponsor should be contacted for further clarification/information
JGF: Conceptualization, Writing—original draft, Writing—review & editing. LGB: Writing—review & editing. TK: Writing—review & editing. CJW: Writing—review & editing. SIK: Writing—review & editing. MDB: Conceptualization, Writing—review & editing, Supervision. All authors read and approved the submitted version.
TK and CJW are employees and stockholders of Karyopharm Therapeutics. All the other authors declare no conflicts of interest.
Not applicable.
Not applicable.
Not applicable.
Not applicable.
This work was supported by Karyopharm Therapeutics and the John Goldman Fellowship Follow-up Award from Leukaemia UK (to MDB). Karyopharm Therapeutics reviewed the manuscript for scientific accuracy prior to submission but had no role in study design, data collection, analysis, interpretation, or writing of the manuscript; the other provider of funds had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
© The Author(s) 2025.
Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.